| |
|
Presenting author |
# |
Title |
 |
|
| |
 |
Gerding, D. |
INV1 |
KEYNOTE LECTURE - MILESTONES IN C. difficile RESEARCH |
|
|
| |
|
Bouza, E. |
INV2 |
THE SPECTRUM OF C. difficile INFECTION (CDI) IN A GENERAL HOSPITAL. CASES AND SITUATIONS FROM THE REAL LIFE |
|
|
| |
|
Riley, T. |
INV3 |
THE “ONE HEALTH” PARADIGM AND C. difficile |
|
|
| |
|
Martín-Burriel, I. |
OP1 |
COMPARATIVE GENOME ANALYSIS OF Clostridium difficile STRAINS ISOLATED FROM DOMESTIC AND WILD ANIMALS REVEALS HIGH SIMILARITY WITH HUMAN STRAINS |
|
|
| |
|
Banks, A. |
OP2 |
COMMUNITY ASSOCIATED Clostridium difficile INFECTION (CDI) IN SCOTLAND – A SENTINEL STUDY |
|
|
| |
|
Cairns, M. |
OP3 |
THE GLOBAL PHYLOGENY OF Clostridium difficile TOXIN A-B+ PCR RIBOTYPE 017 |
|
|
| |
|
McBride, S. |
INV4 |
NOVEL REGULATORY MECHANISMS CONTROL SPORULATION INITIATION IN C. difficile |
|
|
| |
|
Salgado, P. |
OP4 |
THE MOTHER CELL TO FORESPORE CHANNEL HAS A CENTRAL ROLE IN SPORE MORPHOGENESIS, PROTEIN LOCALISATION AND PEPTIDOGLYCAN REMODELING |
|
|
| |
|
Sorg, J. |
OP5 |
SPORE CORTEX HYDROLYSIS PRECEDES DPA RELEASE DURING C. difficile SPORE GERMINATION |
|
|
| |
|
Pedneault, L. |
OP6 |
A PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A Clostridium difficile VACCINE ADMINISTERED WITH OR WITHOUT ALUMINUM HYDROXIDE, IN A 3-DOSE REGIMEN IN HEALTHY ADULTS AGED 50 TO 85 YEARS |
|
|
| |
|
Therien, A. |
OP7 |
EPITOPES AND MECHANISMS OF ACTION OF THE Clostridium difficile TOXIN-NEUTRALIZING ANTIBODIES ACTOXUMAB AND BEZLOTOXUMAB |
|
|
| |
|
Quemeneur, L. |
OP8 |
Clostridium difficile TOXOID VACCINE CONFERS CROSS- PROTECTION AGAINST PREVALENT CIRCULATING C. difficile VARIANT STRAINS IN NON-CLINICAL SETTINGS |
|
|
| |
|
von Eichel-Streiber, A. |
OP9 |
DIFFERENTIAL SYSTEMIC AND MUCOSAL ANTI-TOXIN RESPONSES AMONG PATIENTS INFECTED WITH THE EPIDEMIC 027 STRAIN OF C. difficile |
|
|
| |
|
Bajaj-Elliott, M. |
OP10 |
Clostridium difficile-INDUCED ER STRESS PROMOTES MACROPHAGE NLRP3 MEDIATED INFLAMMASOME ACTIVATION |
|
|
| |
|
Guery, B. |
INV5 |
TREATMENT OF CDI - PRESENT AND FUTURE |
|
|
| |
|
Louie, T. |
INV6 |
PRACTICAL ASPECTS OF FECAL MICROFLORA TRANSPLANTATION (FMT) FOR CDI |
|
|
| |
|
Fitzpatrick, F. |
INV7 |
THE CARROT OR STICK? USING HEALTHCARE-ASSOCITED C. difficile INFECTION RATES AS A PERFORMANCE MANAGEMENT TOOL |
|
|
| |
|
Dubberke, E. |
INV8 |
TRANSMISSION AND FUTURE PREVENTION STRATEGIES |
|
|
| |
|
Khanafer, N. |
OP11 |
FACTORS ASSOCIATED WITH SEVERE Clostridium difficile INFECTION ACCORDING TO 4 DIFFERENT SEVERITY DEFINITIONS |
|
|
| |
|
Ivarsson, M. |
OP12 |
THERAPEUTIC POTENTIAL OF SMALL MOLECULE TRIGGERS OF PRE-EMPTIVE C. difficile TOXIN B AUTO-PROTEOLYSIS |
|
|
| |
|
Barbut, F. |
INV9 |
DIAGNOSIS OF Clostridium difficile INFECTIONS: WHEN AND HOW? |
|
|
| |
|
Janoir, C. |
INV10 |
C. difficile VIRULENCE FACTORS |
|
|
| |
|
Corver, J. |
OP13 |
A NOVEL SECRETED METALLOPROTEASE (CD2830) FROM Clostridium difficile CLEAVES SPECIFIC PROLINE SEQUENCES IN LPXTG CELL SURFACE PROTEINS |
|
|
| |
|
Kirk, J.A. |
OP14 |
THE Clostridium difficile S-LAYER: A MULTI-FUNCTIONAL VIRULENCE FACTOR AND ANTI-BACTERIAL TARGET |
|
|
| |
|
Sekulovic, O. |
OP15 |
THE PHASE-VARIABLE CELL WALL PROTEIN CwpV CONFERS PHAGE RESISTANCE TO Clostridium difficile |
|
|
| |
|
Spigaglia, P. |
INV11 |
ANTIBIOTIC RESISTANCE IN C. difficile – RECENT ADVANCES |
|
|
| |
|
Faulds-Pain, A. |
OP16 |
INVESTIGATING THE POST-TRANSLATIONAL MODIFICATION OF THE Clostridium difficile FLAGELLIN |
|
|
| |
|
Peltier, J. |
OP17 |
CYCLIC-DI-GMP REGULATES PRODUCTION OF SORTASE B SUBSTRATES OF Clostridium difficile AND THEIR SURFACE EXPOSURE THROUGH ZMPI PROTEASE-MEDIATED CLEAVAGE |
|
|
| |
|
Young V. |
INV12 |
C. difficile INFECTION: THE TANGLED WEB OF EPITHELIUM, MICROBIOTA AND PATHOGEN |
|
|
| |
|
Carlucci, C. |
OP18 |
CHARACTERIZATION OF A DEFINED MICROBIAL ECOSYSTEM THERAPEUTIC FOR THE TREATMENT OF Clostridium difficile INFECTION |
|
|
| |
|
Govoni, G. |
OP19 |
AVIDOCIN-CDs: TARGETABLE, MICROBIOTA-FRIENDLY BACTERICIDAL AGENTS FOR TREATMENT AND PREVENTION OF CDI |
|
|
| |
|
Chilton, C. |
OP20 |
POSSIBLE FAECAL MICROBIOTA MEDIATED INHIBITION OF THE BIOACTIVITY OF Clostridium difficile INFECTION (CDI) ANTIBIOTIC TREATMENT AGENTS |
|
|
